Solid Biosciences Inc. Increase (Decrease) in Deferred Revenue
Solid Biosciences Inc. (SLDB) reported Increase (Decrease) in Deferred Revenue of -$8.08 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2024-03-13
- Solid Biosciences Inc. increase (decrease) in deferred revenue for the quarter ending 2022-12-31 was $0.00.
- Solid Biosciences Inc. increase (decrease) in deferred revenue for the quarter ending 2022-09-30 was $0.00.
- Solid Biosciences Inc. increase (decrease) in deferred revenue for the quarter ending 2022-06-30 was -$6.17M.
- Solid Biosciences Inc. increase (decrease) in deferred revenue for the quarter ending 2022-03-31 was -$1.91M.
- Solid Biosciences Inc. increase (decrease) in deferred revenue for fiscal 2022 was -$8.08M.
- Solid Biosciences Inc. increase (decrease) in deferred revenue for fiscal 2021 was -$12.64M, a 161.00% decline from fiscal 2020.
- Solid Biosciences Inc. increase (decrease) in deferred revenue for fiscal 2020 was $20.72M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | -$6.17M derived: sum of 3 quarters · filed 2024-03-13 | -$8.08M 10-K · filed 2024-03-13 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$6.17M derived: sum of 2 quarters · filed 2023-11-08 | -$8.08M 10-Q · filed 2023-11-08 | -$11.13M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | -$6.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$8.08M 10-Q · filed 2023-08-14 | -$11.13M derived: sum of 3 quarters · filed 2024-03-13 | -$14.35M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | -$1.91M 10-Q · filed 2023-05-11 | -$4.96M derived: sum of 2 quarters · filed 2024-03-13 | -$8.18M derived: sum of 3 quarters · filed 2024-03-13 | -$11.49M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | -$3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$6.27M derived: sum of 2 quarters · filed 2024-03-13 | -$9.58M derived: sum of 3 quarters · filed 2024-03-13 | -$12.64M 10-K · filed 2024-03-13 |
| 2021-09-30 | -$3.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$6.54M derived: sum of 2 quarters · filed 2022-11-10 | -$9.59M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$3.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$6.36M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$3.06M 10-Q · filed 2022-04-27 | |||
| 2020-12-31 | $20.72M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |